Press Releases

Filter by:
February 11, 2023   |   Press Release

Cerveau Technologies, Inc, is now a subsidiary of Lantheus

January 16, 2023   |   Business Wire

Cerveau Technologies Inc. and Prothena Sign Agreement to Provide Novel Tau Imaging Biomarker for Research and Development of Investigational Therapeutics for Neurodegenerative Diseases

November 15, 2022   |   Critical Path Institute

C-Path and Cerveau Technologies, Inc. Announce Data Sharing Collaboration to Accelerate Drug Development for Alzheimer’s Disease and Related Dementias

September 1, 2022   |   Business Wire

Cerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research

May 4, 2020   |   Business Wire

Cerveau Technologies, Inc. Announces Collaboration with University College of London

March 20, 2020   |   Business Wire

Cerveau Technologies, Inc. Announces Collaboration with Alector, Inc.

November 14, 2019   |   Business Wire

Cerveau Technologies, Inc. Announces Initiation of Japanese Phase I Study

September 27, 2019   |   Business Wire

Cerveau Technologies Inc. Signs Research Agreement with Takeda to Provide Novel Tau Imaging Agent

May 19, 2019   |   Business Wire

Cerveau Technologies, Inc. Announces a Partnership with LuMind IDSC Foundation to Study Accumulation of Neurofibrillary Tau in Down Syndrome

March 22, 2019   |   Business Wire

Cerveau Technologies Inc. Signs Research Agreement with Eisai Inc., for Novel Tau Imaging Agent

This product candidate is an investigational drug that has not yet been approved as safe and effective.